CLOSE
MENU
Bausch + Lomb History + Heritage
Magnifying lens on top of book
Magnifying lens on top of book

History + Heritage

A Legacy of Innovation

For more than a century and a half, Bausch + Lomb has been at the forefront of optical innovation. Our unique advancements underscore the quality and craftsmanship of our people around the world.

1853

J. J. Bausch opens an optical goods store in Rochester, New York. He borrows $60 from friend Henry Lomb to expand the business, sealing the deal with a handshake.

history image element
1861

J. J. Bausch’s revolutionary Vulcanite eyeglass frames become the first great success for the young company.

history image element
1875

Bausch + Lomb begins microscope production.

history image element
1887

Edward Bausch, J. J.’s son, patents the “between the lens” iris diaphragm and shutter, helping to give rise to snapshot photography.

history image element
1902

Bausch + Lomb introduces the Balopticon slide projector.

history image element
1933

Bausch + Lomb introduces Honorary Science Award for high school students; hundreds of thousands of awards have been bestowed since.

history image element
1936

The first Ray-Ban aviator goggles for military pilots are produced.

history image element
1953

The first films made with the CinemaScope lens premiered in movie theaters, bringing widescreen movie projection to the big screen.

history image element
1954

Bausch + Lomb receives an Honorary Award from the Academy of Motion Picture Arts and Sciences for contributions to the advancement of the motion-picture industry.

history image element
1964

First images of the surface of the moon are taken using Bausch + Lomb Super Baltar lenses.

history image element
1971

Bausch + Lomb launches SofLens® contact lenses, the first mass-produced soft contact lens in the U.S.

history image element
1981

The company creates its first toric contact lens, and the following year launches its first bifocal contact lens.

history image element
1983

Polymer Technology Corporation, a leader in rigid gas permeable contact lenses and solutions, is acquired; the Boston® contact lenses and solutions brands join the Bausch + Lomb portfolio.

history image element
1986

Bausch + Lomb expands into ophthalmic pharmaceuticals by acquiring Dr. Mann Pharma, and then the following year, Pharmafair Inc.

history image element
1987

ReNu® multipurpose solution for soft contact lenses is launched.

history image element
1996

Bausch + Lomb releases 15 new pharmaceutical products, greatly expanding its pharmaceutical portfolio.

history image element
1997

Bausch + Lomb establishes a surgical business unit through acquisitions of Chiron Vision and Storz® Ophthalmics, focusing on cataract, refractive and vitreoretinal surgery.

history image element
1998

LOTEMAX® (loteprednol etabonate ophthalmic suspension) 0.5% and Alrex® (loteprednol etabonate ophthalmic suspension) 0.2% are launched.

history image element
1999

PureVision® contact lenses, the first silicone hydrogel contact lenses in the U.S., are launched.

history image element
2001

Bausch + Lomb launches PreserVision® brand of eye vitamins, after supporting the landmark National Eye Institute AREDS study.

history image element
2005

Retisert® (fluocinolone acetonide intravitreal implant) 0.59 mg is approved by the FDA as an orphan drug.

history image element
2006

Bausch + Lomb receives FDA clearance for SofLens® daily disposable contact lenses.

history image element
2007

The Stellaris® vision enhancement system is launched, breaking new ground in cataract surgery.

history image element
2008

Eyeonics is acquired, adding Crystalens® IOL—the first FDA-approved accommodating intraocular lens for the treatment of cataracts—to the Bausch + Lomb portfolio.

history image element
2009

Besivance® (besifloxacin ophthalmic suspension) 0.6% is introduced.

history image element
2010

Biotrue® multi-purpose solution and PureVision®2 contact lenses are introduced.

history image element
2011

Bausch + Lomb launches LOTEMAX® Ointment (loteprednol etabonate ophthalmic ointment) 0.5%.

history image element
2012

Bausch + Lomb completes the acquisition of ISTA Pharmaceuticals and adds Bromday® (bromfenac ophthalmic solution) 0.09%, Bepreve® (bepotastine besilate ophthalmic solution) 1.5%, Istalol® (timolol maleate ophthalmic solution) 0.5%, and Vitrase® (hyaluronidase for injection) to its product portfolio.

history image element
2012

Bausch + Lomb receives FDA approval for enVista® intraocular lens.

history image element
2012

Bausch + Lomb receives FDA clearance for Biotrue® ONEday daily disposable contact lenses.

history image element
2012

Bausch + Lomb and Technolas Perfect Vision receive FDA clearance for Victus® Femtosecond Laser Platform.

history image element
2013

LOTEMAX® Gel (loteprednol etabonate ophthalmic gel) 0.5% and PROLENSA® (bromfenac ophthalmic solution) 0.07% are introduced.

history image element
2013

Bausch + Lomb receives FDA approval for TRULIGN® toric intraocular lens.

history image element
2013

PreserVision® AREDS 2 Formula eye vitamin and mineral supplement is introduced.

history image element
2014

Bausch + Lomb ULTRA® silicone hydrogel monthly contact lenses and Biotrue® ONEday for Presbyopia contact lenses are introduced.

history image element
2015

Synergetics USA Inc. is acquired, expanding the surgical product portfolio.

history image element
2016

Acquisition of Alden Optical Laboratories increases access to specialty modalities, including the Zenlens™ scleral lens and NovaKone® soft contact lens for keratoconus.

history image element
2016

Bausch + Lomb ULTRA® for Presbyopia is launched.

history image element
2017

Bausch + Lomb launches Stellaris Elite® vision enhancement system for cataract and retina surgery.

history image element
2017

Bausch + Lomb receives FDA approval for VYZULTA® (latanoprostene bunod ophthalmic solution) 0.024%.

history image element
2017

Bausch + Lomb ULTRA® for Astigmatism and Biotrue® ONEday for Astigmatism are introduced.

history image element
2018

First-in-class eyeTELLIGENCE™ application is now available exclusively on the Stellaris Elite® vision enhancement system.

history image element
2018

Bausch + Lomb launches LUMIFY® redness reliever eye drops, the first and only over-the-counter eye drop with low-dose brimonidine tartrate for the relief of eye redness.

history image element
2019

LOTEMAX® SM (loteprednol etabonate ophthalmic gel) 0.38% receives FDA approval; enVista® toric MX60ET hydrophobic acrylic intraocular lens (IOL) with StableFlex™ technology is launched.

history image element
2019

Bausch + Lomb ULTRA® Multifocal for Astigmatism is launched.

history image element
2020

Bausch + Lomb launches INFUSE® daily disposable contact lenses.

history image element
2021

Bausch + Lomb receives FDA approval for ClearVisc™ dispersive ophthalmic viscosurgical device (OVD).

history image element
2022

Bausch + Lomb launches XIPERE® (triamcinolone acetonide injectable suspension) for suprachoroidal use.

history image element